BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37333086)

  • 1. Myeloid differentiation factor-2/LY96, a new predictive biomarker of metastasis in prostate cancer: Clinical implications as a potential therapeutic target.
    Ferrari M; Wang L; Hoeppner L; Hahm E; Yu J; Kuzel T; Mansini A
    Res Sq; 2023 Jun; ():. PubMed ID: 37333086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target.
    Ferrari MG; Jimenez-Uribe AP; Wang L; Hoeppner LH; Murugan P; Hahm E; Yu J; Kuzel TM; Gradilone SA; Mansini AP
    Oncogene; 2024 Feb; 43(7):484-494. PubMed ID: 38135694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
    Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
    Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
    J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
    Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
    Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
    Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
    [No Abstract]   [Full Text] [Related]  

  • 8. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
    Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
    Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
    Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
    Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resetting the Bar of Castration Resistance - Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer.
    Shore ND; Morgans AK; Ryan CJ
    Clin Genitourin Cancer; 2021 Jun; 19(3):199-207. PubMed ID: 33129718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.
    Mori K; Kimura T; Fukuokaya W; Iwatani K; Sakanaka K; Kurokawa G; Yanagisawa T; Sasaki H; Miki J; Shimomura T; Miki K; Hatano T; Endo K; Egawa S
    Int J Clin Oncol; 2020 Mar; 25(3):479-485. PubMed ID: 31512007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying and treating ROBO1
    Ferrari MG; Ganaie AA; Shabenah A; Mansini AP; Wang L; Murugan P; Davicioni E; Wang J; Deng Y; Hoeppner LH; Warlick CA; Konety BR; Saleem M
    Prostate; 2020 Sep; 80(13):1045-1057. PubMed ID: 32687658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective targeting of the TLR4 co-receptor, MD2, prevents colon cancer growth and lung metastasis.
    Rajamanickam V; Yan T; Xu S; Hui J; Xu X; Ren L; Liu Z; Liang G; Wang O; Wang Y
    Int J Biol Sci; 2020; 16(8):1288-1302. PubMed ID: 32210720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer.
    Qin J; Lee HJ; Wu SP; Lin SC; Lanz RB; Creighton CJ; DeMayo FJ; Tsai SY; Tsai MJ
    J Clin Invest; 2014 Nov; 124(11):5013-26. PubMed ID: 25295534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.
    Altschuler J; Stockert JA; Kyprianou N
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TUBB3 is associated with PTEN, neuroendocrine differentiation, and castration resistance in prostate cancer.
    Sekino Y; Han X; Babasaki T; Miyamoto S; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Takeshima Y; Yasui W; Matsubara A
    Urol Oncol; 2021 Jun; 39(6):368.e1-368.e9. PubMed ID: 33771409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid hormone synthetic pathways in prostate cancer.
    Mostaghel EA
    Transl Androl Urol; 2013 Sep; 2(3):212-227. PubMed ID: 25379460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wnt Signaling and Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Kishore C; Zi X
    Curr Pharmacol Rep; 2023 Oct; 9(5):261-274. PubMed ID: 37994344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor.
    Tilki D; Schaeffer EM; Evans CP
    Eur Urol Focus; 2016 Dec; 2(5):499-505. PubMed ID: 28723515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer.
    Ammirante M; Luo JL; Grivennikov S; Nedospasov S; Karin M
    Nature; 2010 Mar; 464(7286):302-5. PubMed ID: 20220849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.